Pharmaceutical & Analytical Research & Development, Hoffmann La-Roche, Nutley, NJ 07110, USA.
Pharm Dev Technol. 2013 Mar-Apr;18(2):490-503. doi: 10.3109/10837450.2012.723717. Epub 2012 Sep 26.
To evaluate and optimize sodium lauryl sulfate (SLS) and magnesium stearate (Mg.St) levels, with respect to dissolution and compaction, in a high dose, poorly soluble drug tablet formulation.
A model poorly soluble drug was formulated using high shear aqueous granulation. A D-optimal design was used to evaluate and model the effect of granulation conditions, size of milling screen, SLS and Mg.St levels on tablet compaction and ejection. The compaction profiles were generated using a Presster(©) compaction simulator. Dissolution of the kernels was performed using a USP dissolution apparatus II and intrinsic dissolution was determined using a stationary disk system.
Unlike kernels dissolution which failed to discriminate between tablets prepared with various SLS contents, the intrinsic dissolution rate showed that a SLS level of 0.57% was sufficient to achieve the required release profile while having minimal effect on compaction. The formulation factors that affect tablet compaction and ejection were identified and satisfactorily modeled. The design space of best factor setting to achieve optimal compaction and ejection properties was successfully constructed by RSM analysis.
A systematic study design helped identify the critical factors and provided means to optimize the functionality of key excipient to design robust drug product.
评估和优化月桂基硫酸钠(SLS)和硬脂酸镁(Mg.St)的水平,以改善高剂量难溶性药物片剂的溶出度和可压性。
采用高剪切水制粒法对模型难溶性药物进行制剂研究。采用 D-最优设计评估和建立制粒条件、制粒筛网大小、SLS 和 Mg.St 水平对片剂压缩和推出的影响模型。采用 Presster(©)压片机压缩模拟器生成压缩曲线。采用 USP 溶出仪 II 进行颗粒的溶出度研究,采用固定盘系统测定固有溶出度。
与各种 SLS 含量的片剂的颗粒溶出度无法区分不同之处不同,固有溶出度表明,SLS 水平为 0.57%即可达到所需的释放曲线,而对压缩的影响最小。确定了影响片剂压缩和推出的制剂因素,并对其进行了合理建模。通过 RSM 分析成功构建了达到最佳压缩和推出性能的最佳因素设置的设计空间。
系统的研究设计有助于确定关键因素,并提供优化关键赋形剂功能的手段,以设计稳健的药物产品。